Luminex ® xMAP ® technology is an effective strategy for high-definition human leukocyte antigen typing of cord blood units prior to listing

Abstract

Introduction:

Allele-level donor–recipient match at HLA-A, HLA-B, HLA-C and HLA-DRB1 loci impacts the outcome after cord blood transplantation for hematologic malignancies and modifies the strategy of donor selection. High definition of both class I and II HLA loci at time of listing is a way to improve the attractiveness of cord blood bank inventories, reducing the time for donor search and procurement and simplifying donor choice, in particular, for patients of non-European heritage.

Methods:

In 2014, Luminex^® xMAP^® technology was introduced in our laboratory practice and was applied to cord blood units typing. In this study, we evaluated the impact of this strategy in comparison with the platform in use until 2013, relying on LiPA reverse polymerase chain reaction–sequence-specific oligonucleotide (revPCR-SSO) plus polymerase chain reaction–sequence-specific primer (PCR-SSP).

Results:

In 2014, the time for testing was shorter (141 vs 181 days on average), the number of test repetitions was lower (in particular for HLA-A locus, p = 0.026), and the cost reduced (240.7 vs 395.6 euros per unit on average) compared to 2013, demonstrating that Luminex xMAP technology is superior to the previous approach.

Conclusion:

Luminex xMAP platform has useful application in cord blood banking programs, to achieve high-definition HLA typing of cord blood units at the time of banking in a quick, accurate, and cost-effective manner.

Keywords

Cord blood human leukocyte antigen typing

Get full access to this article

View all access options for this article.

References

Ballen

Gluckman

Broxmeyer

HE.

Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122(4): 491–498.

Rocha

Gluckman

Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft-and transplantation-related factors. Br J Haematol 2009; 147(2): 262–274.

Ruggeri

Paviglianiti

Gluckman

et al . Impact of HLA in cord blood transplantation outcomes. HLA 2016; 87(6): 413–421.

Eapen

Klein

Ruggeri

et al . Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014; 123(1): 133–140.

Oran

Cao

Saliba

et al . Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 2015; 100(10): 1361–1370.

Brunstein

Petersdorf

DeFor

et al . Impact of allele-level HLA mismatch on outcomes in recipients of double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2016; 22(3): 487–492.

Dahi

Ponce

Devlin

et al . Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection. Bone Marrow Transplant 2014; 49(9): 1184–1186.

Dunbar

SA.

Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363(1–2): 71–82.

Testi

Andreani

Luminex-based methods in high-resolution HLA typing. Methods Mol Biol 2015; 1310: 231–245.

10.

Jordan

McWhinnie

Turner

et al . Comparison of HLA-DRB1 typing by DNA-RFLP, PCR-SSO and PCR-SSP methods and their application in providing matched unrelated donors for bone marrow transplantation. Tissue Antigens 1995; 45(2): 103–110.

11.

Welsh

Bunce

Molecular typing for the MHC with PCR-SSP. Rev Immunogenet 1999; 1(2): 157–176.

12.

Heinemann

FM.

HLA genotyping and antibody characterization using the Luminex™ Multiplex Technology. Transfus Med Hemother 2009; 36(4): 273–278.

13.

Eapen

Klein

Sanz

et al . Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12(13): 1214–1221.